54 related articles for article (PubMed ID: 20833444)
1. Intermittent etanercept therapy in pediatric patients with psoriasis.
Siegfried EC; Eichenfield LF; Paller AS; Pariser D; Creamer K; Kricorian G
J Am Acad Dermatol; 2010 Nov; 63(5):769-74. PubMed ID: 20833444
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.
Gottlieb AB; Langley RG; Strober BE; Papp KA; Klekotka P; Creamer K; Thompson EH; Hooper M; Kricorian G
Br J Dermatol; 2012 Sep; 167(3):649-57. PubMed ID: 22533447
[TBL] [Abstract][Full Text] [Related]
3. Etanercept in psoriasis: the evidence of its therapeutic impact.
Thomson A
Core Evid; 2007 Mar; 2(1):51-62. PubMed ID: 21221197
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis.
Paller AS; Siegfried EC; Pariser DM; Rice KC; Trivedi M; Iles J; Collier DH; Kricorian G; Langley RG
J Am Acad Dermatol; 2016 Feb; 74(2):280-7.e1-3. PubMed ID: 26775775
[TBL] [Abstract][Full Text] [Related]
5. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
Gordon K; Papp K; Poulin Y; Gu Y; Rozzo S; Sasso EH
J Am Acad Dermatol; 2012 Feb; 66(2):241-51. PubMed ID: 21752491
[TBL] [Abstract][Full Text] [Related]
7. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.
Kimball AB; Rothman KJ; Kricorian G; Pariser D; Yamauchi PS; Menter A; Teller CF; Aras G; Accortt NA; Hooper M; Rice KC; Gelfand JM
J Am Acad Dermatol; 2015 Jan; 72(1):115-22. PubMed ID: 25264239
[TBL] [Abstract][Full Text] [Related]
8. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011.
Armstrong AW; Schupp C; Wu J; Bebo B
PLoS One; 2012; 7(12):e52935. PubMed ID: 23285231
[TBL] [Abstract][Full Text] [Related]
9. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis.
Ortonne JP; Paul C; Berardesca E; Marino V; Gallo G; Brault Y; Germain JM
Br J Dermatol; 2013 May; 168(5):1080-7. PubMed ID: 23013207
[TBL] [Abstract][Full Text] [Related]
10. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.
Bagel J; Lynde C; Tyring S; Kricorian G; Shi Y; Klekotka P
J Am Acad Dermatol; 2012 Jul; 67(1):86-92. PubMed ID: 22014541
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
Lebwohl M; Leonardi C; Griffiths CE; Prinz JC; Szapary PO; Yeilding N; Guzzo C; Li S; Hsu MC; Strober B
J Am Acad Dermatol; 2012 May; 66(5):731-41. PubMed ID: 21930328
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.
Papp KA; Poulin Y; Bissonnette R; Bourcier M; Toth D; Rosoph L; Poulin-Costello M; Setterfield M; Syrotuik J
J Am Acad Dermatol; 2012 Feb; 66(2):e33-45. PubMed ID: 20850895
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.
Landells I; Marano C; Hsu MC; Li S; Zhu Y; Eichenfield LF; Hoeger PH; Menter A; Paller AS; Taieb A; Philipp S; Szapary P; Randazzo B
J Am Acad Dermatol; 2015 Oct; 73(4):594-603. PubMed ID: 26259989
[TBL] [Abstract][Full Text] [Related]
15. Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexibledosing etanercept in patients with plaque psoriasis in Greece.
Rigopoulos D; Patsatsi A; Antoniou C; Sotiriadis D; Schulze AR; Boubouchairopoulou N; Skiadas I; Tsekouras V; Hernandez Daly AC
Dermatol Reports; 2022 Nov; 14(4):9265. PubMed ID: 36483226
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of biological agents for the treatment of pediatric patients with psoriasis: A bayesian analysis of six high-quality randomized controlled trials.
Cai XC; Ru Y; Liu L; Sun XY; Zhou YQ; Luo Y; Chen JL; Zhang M; Wang CX; Li B; Li X
Front Immunol; 2022; 13():896550. PubMed ID: 36081503
[TBL] [Abstract][Full Text] [Related]
17. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.
Welzel T; Winskill C; Zhang N; Woerner A; Pfister M
Pediatr Rheumatol Online J; 2021 Mar; 19(1):46. PubMed ID: 33766063
[TBL] [Abstract][Full Text] [Related]
18. FDA Approved Biologics: Can Etanercept and Ustekinumab be Considered a First-Line Systemic Therapy for Pediatric/Adolescents in Moderate to Severe Psoriasis? A Systematic Review.
Aslam N; Saleem H; Murtazaliev S; Quazi SJ; Khan S
Cureus; 2020 Aug; 12(8):e9812. PubMed ID: 32953323
[TBL] [Abstract][Full Text] [Related]
19. Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend.
Saikaly SK; Mattes M
Cureus; 2016 Jun; 8(6):e652. PubMed ID: 27462478
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF agents for paediatric psoriasis.
Sanclemente G; Murphy R; Contreras J; García H; Bonfill Cosp X
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010017. PubMed ID: 26598969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
